Clinical Trials
144 trialsNCT05669339 2026-06-04
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT06096779 2026-06-01
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT07483359 2026-05-28
CONV3RSION
First Hospital of China Medical University
Phase 2 Recruiting
NCT04982653 2026-05-26
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05620771 2026-05-26
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Recruiting
NCT06953089 2026-05-22
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 2 Recruiting
NCT07493668 2026-05-22
FLEX-HCC
CHA University
Phase 2 Recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT07012798 2026-05-13
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07413354 2026-05-12
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT06852820 2026-05-08
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT07062055 2026-05-08
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07014150 2026-05-05
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07122089 2026-05-05
IOSPHERE
Center Eugene Marquis
Phase 2 Recruiting
NCT06902246 2026-05-01
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07560488 2026-05-01
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07560566 2026-05-01
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
National Taiwan University Hospital
Phase 2 Recruiting
NCT04472767 2026-04-30
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
University of California, Irvine
Phase 2 Recruiting
NCT07274774 2026-04-28
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07219459 2026-04-27
GDFATHERHCC01
CatalYm GmbH
Phase 2 Recruiting
NCT04114136 2026-04-24
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT07422753 2026-04-24
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07521852 2026-04-22
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT06860490 2026-04-21
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
Phase 2 Recruiting
NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Phase 2 Recruiting
NCT06553885 2026-04-01
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07312292 2026-03-30
RADIANT
UMC Utrecht
Phase 2 Recruiting
NCT07331883 2026-03-27
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07010497 2026-03-18
IAPETUS
Asan Medical Center
Phase 2 Recruiting
NCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT07052253 2026-03-16
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Akeso
Phase 2 Recruiting
NCT05901519 2026-03-13
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT06218420 2026-03-03
TRANSRAD-01
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06789848 2026-02-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06330064 2026-02-12
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Phase 2 Recruiting
NCT07174570 2026-01-28
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
Phase 2 Recruiting
NCT05366829 2026-01-20
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT07324824 2026-01-16
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07337421 2026-01-13
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
Phase 2 Recruiting
NCT07337460 2026-01-13
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
Phase 2 Recruiting
NCT07327034 2026-01-08
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Abbisko Therapeutics Co, Ltd
Phase 2 Recruiting
NCT07324304 2026-01-07
NWRD06 DNA Plasmid for HCC After Curative Resection.
Newish Technology (Beijing) Co., Ltd.
Phase 2 Recruiting